Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
Epcoritamab combined with lenalidomide and rituximab outperforms standard chemotherapy approaches for multiply relapsed follicular lymphoma without requiring traditional chemotherapy.
An adjusted indirect comparison using Memorial Sloan Kettering and COTA EHR data compared epcoritamab+R2 from the EPCORE NHL-2 trial against real-world R2/chemoimmunotherapy in R/R follicular lymphoma patients. Epcoritamab+R2 demonstrated significantly superior response rates and survival outcomes across all endpoints, supporting it as a chemotherapy-free frontrunner for multiply relapsed FL.
What the study was
- Study design
- comparative_effectiveness_analysis
- Population
- Patients with relapsed/refractory follicular lymphoma
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Oncoimmunology
Why it surfaced
Pivotal comparative effectiveness data for FDA-approved epcoritamab+R2 vs. current standard CIT in R/R FL using patient-level EHR matching; confirms clinical superiority in a difficult-to-treat population with no curative standard; directly relevant to clinical practice change.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.